Novo Nordisk VP to Speak at Cytokines Conference Jan 31, 2013 in San Diego, CA

Ian Ahnfelt-Ronne, Corporate Vice President at Novo Nordisk A/S Will Give a Featured Presentation at the 11th Cytokines and Inflammation Conference (Jan 31-Feb 1, 2013 in San Diego, CA)

Ian Ahnfelt-Ronne, Corporate Vice President at Novo Nordisk A/S will give a featured presentation on “Potential Role of IL-20 in the Pathogenesis of Rheumatoid Arthritis” at the 11th Cytokines and Inflammation Conference to be held in San Diego, CA on January 31 – February 1, 2013 by GTC.

NNC0109-0012 (a novel, recombinant human monoclonal IgG4 anti-IL-20 antibody) is currently being investigated in patients with Rheumatoid Arthritis [RA]. NNC0109-0012 binds to human IL-20 with high affinity, and neutralizes the activity of IL-20 in cell-based assays. NNC0109-0012. Data from a phase 1 single-dose trial in healthy volunteers and patients with RA, and a multiple-dose phase 1 trial in RA patients did not raise any safety concerns. In a recent phase 2a trial with weekly administration of NNC0109-0012 and placebo to patients with RA reduced disease activity was shown in the RA patients, with significant improvement in DAS28 (CRP) observed after 1 week and through the 12 weeks of treatment. For the sub-group of RF/ACPA-positive patients, the treatment effects of NNC0109-0012 on all disease parameters were significantly larger than for all randomized patients at week 12, and were sustained during the 13 weeks follow-up period after cessation of drug administration. Again, treatment with NNC0109-0012 revealed no safety concerns. The data from this trial support the concept that IL-20 may play a role in the pathogenesis of RA. Further clinical testing of NNC0109-0012 in RA patients is in progress.

The GTC Cytokines and Inflammation conferences have become an established meeting point for academic scientists and industry clinical developers to exchange their complementary approaches in the field of cytokine biology. The organizations participating are a great selection of innovative medical organizations from academia (City of Hope, NCI, NIH, USC, Sanford-Burnham, Cleveland Clinic, UCLA, University of Florida, etc.), industry (Amgen, Bristol-Myers Squibb, Genentech, HUMIGEN, MedImmune, Biogen Idec, Merck Serono, Novo Nordisk, etc.) and, last but not -by any means- least, the US FDA.

This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of a workshop, this track and three other concurrent tracks:
1) 5th Immunotherapeutics & Immunomonitoring
2) 2nd Allergy & Respiratory Drug Discovery
3) Immunotoxicity & Immunogenicity
4) Workshop: Immune Responses in Tumor Microenvironment

For more information, please visit

Contact Details

Company Name: GTC Conferences
Issued By: Eileen Zhao
Phone: 6262566405
Address: Global Technology Community | 635 W. Foothill Blvd | Monrovia, CA 91016
City: San Diego
State: California
Zip: 91016
Country: United States
Website: Visit the website

Keywords : cytokines,

by Eileen Zhao (few years ago!)

Latest Press Releases

The Mad Hatter Now Offer a Full Line of Hearth Products and Full Line of Grills

Diabetes Insulin Delivery Pens Market Research Report 2018

Dr Kapadia Provides Tips to Patients Interested in Hair Transplant Procedures

love vashikaran specialist

Solar Blanket Sales Market Report 2018

Spring Bottled Water Market Insights, Forecast to 2025

Biochemical Incubator Sales Market Report 2018

Quinine Sulphate Sales Market Report 2018

Automotive Chassisc System Market Insights, Forecast to 2025

2,6-Dicarboxypyridine market size in key regions like North America, Europe, Asia Pacific an..

Remove this press release ?

Due to extra work required to remove the press-releases we have started charging $1.99 for press release removal.

Your press release will be removed in 24 hours, once the payment has been received.

Search Press Release
e.g. Business, Computer, etc.